AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1009523
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent (Cyclophosphamide)
Trial: 19291601
Drug: 64-slice CT
RxNorm normalized name: Sklice
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 64-slice CT with 80 cc CM at 5 cc/sec followed by a 50 cc saline chaser bolus containing 20% contrast media
Trial: 17290009
Drug: L-NMMA (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (low dose)
Trial: 17290009
Drug: L-NMMA (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (high dose)
Trial: 9105060
Drug: ONO‐1078 (pranlukast),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO‐1078 (pranlukast), 450 mg twice daily
Trial: 28631682
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy combined with homeovox
Trial: 26508659
Drug: Adenosine treatment
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine treatment for 6 months
Trial: 24594076
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50-100mg daily for 2 days
Trial: 19388861
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between acupuncture and sham treatment
Trial: 15126928
Drug: Immediate antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antihypertensive treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily, hydrochlorothiazide 12.5-25 mg daily)
Trial: 15126928
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment (placebo)
Trial: 15126928
Drug: Immediate antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antihypertensive treatment in diabetic patients (n=492)
Trial: 2197535
Drug: 8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/d cotrimoxazole (TMP/SMX) i.v.
Trial: 2197535
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg aerosolized pentamidine
Trial: 347887
Drug: L-tryptophan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (6 g daily) and ECT
Trial: 26420886
Drug: IVIG (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (0.4 g/kg 10% IVIG every 2 weeks for a total of 5 infusions, 2 g/kg total dose)
Trial: 25529292
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine strain, LTBI, HIV infection, asymptomatic malaria, growth z-scores, childhood anthelminthic treatment, maternal BCG scar
Trial: 21073372
Drug: Irsogladine 4
RxNorm normalized name: irsogladine
DrugBank: Irsogladine (DB13056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irsogladine 4 mg/day
Trial: 15116294
Drug: Levofloxacin administered
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin administered as an infusion of 500 mg/h for 1.5 h (total dose, 750 mg) with additional drugs for specific pathogens (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicillin-resistant S. aureus).
Trial: 8426211
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial therapy with floxuridine, mitomycin, and carmustine (FMB)
Trial: 8426211
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial therapy with floxuridine alone (F)
Trial: 6150140
Drug: Intravenous gammaglobulin
RxNorm normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gammaglobulin prepared by Cohn fractionation of pooled plasma
Trial: 24577097
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of phosphatidylserine enriched with docosahexaenoic acid (PS-DHA)
Trial: 22337277
Drug: Correction group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correction group (received infusion with fresh-frozen plasma and/or platelets)
Trial: 19624554
Drug: Desloratadine (DL)
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine (DL) 5 mg once daily
Trial: 16458655
Drug: Prenatal supplements
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplements with 30 mg of iron as ferrous sulfate (n = 218 women)
Trial: 16458655
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of iron (control group, n = 211 women)
Trial: 8889421
Drug: suxamethonium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium (1 mg kg‐1)
Trial: 8889421
Drug: saline (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (0.02 mL kg‐1)
Trial: 6435961
Drug: L-Lysine monohydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Lysine monohydrochloride 1,248 mg/day
Trial: 6435961
Drug: L-Lysine monohydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Lysine monohydrochloride 624 mg/day
Trial: 6435961
Drug: L-Lysine monohydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Lysine monohydrochloride (both dosages)
Trial: 31009578
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control (6-month delay in treatment)
Trial: 26117247
Drug: Integrated Treatment
RxNorm normalized name: Bag Spike + Integrated Clave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Treatment Adherence Program
Trial: 23623047
Drug: Olmesartan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan at 20 mg/day
Trial: 23623047
Drug: Valsartan at
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan at 80 mg/day
Trial: 20955210
Drug: Low-dose fenoldopam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fenoldopam infusion
Trial: 19164400
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation (exercise training twice weekly for 12 weeks, nutritional and self-care advice, education about disease and energy conservation)
Trial: 8377777
Drug: Broad-spectrum sunscreen
RxNorm normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum sunscreen cream with SPF 17
Trial: 21928714
Drug: Base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base cream (control)
Trial: 3535685
Drug: Bronchodilator (salbutamol)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchodilator (salbutamol)
Trial: 20420955
Drug: Cognitive-behavioural intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural intervention; details on dosage and duration not specified.
Trial: 2685660
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of gangliosides (Cronassial)
Trial: 25337948
Drug: Guided Internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-delivered cognitive behavior therapy (ICBT) for insomnia
Trial: 25337948
Drug: Guided Internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-delivered cognitive behavior therapy (ICBT) for depression
Trial: 20079223
Drug: Domestic Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domestic Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Trial: 20079223
Drug: Imported Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imported Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Trial: 1309865
Drug: DMSA (1050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA (1050 mg/m2 per day for 5 days)
Trial: 1309865
Drug: CaNa2EDTA (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaNa2EDTA (1000 mg/m2 per day intravenously)
Trial: 1309865
Drug: DMSA (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA (350 or 700 mg/m2 per day for 14 days on outpatient basis)
Trial: 1329491
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg naloxone
Trial: 6331037
Drug: 4.8 mg
RxNorm normalized name: menthol 4.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 mg naloxone
Trial: 18344081
Drug: Lornoxicam/morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam/morphine
Trial: 10700888
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with interferon or interleukin-2
Trial: 10700888
Drug: Adjuvant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon-alpha administration
Trial: 10700888
Drug: Cisplatin-based treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based treatment protocols
Trial: 10700888
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with autologous stem-cell support
Trial: 10700888
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen depletion treatment
Trial: 6362585
Drug: Fibronectin-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibronectin-rich plasma cryoprecipitate (2.139 +/‐ 0.161 mg/ml)
Trial: 6362585
Drug: Fibronectin-poor cryoprecipitate
RxNorm normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibronectin-poor cryoprecipitate extracted plasma (placebo, 0.116 +/‐ 0.025 mg/ml)
Trial: 3887350
Drug: Nd‐YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd‐YAG laser treatment
Trial: 16003229
Drug: Chronic corticosteroid
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic corticosteroid therapy (CCST)
Trial: 18077495
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine capsule
Trial: 12925475
Drug: Ibuprofen 15
RxNorm normalized name: Ibuprofen 150 mg and paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 15 mg/kg
Trial: 26316567
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy with intra-arterial rtPA
Trial: 19857068
Drug: Fenugreek bread
RxNorm normalized name: FENUGREEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek bread (5% fenugreek, 56 g)
Trial: 17577460
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with doxazosin and finasteride
Trial: 11562727
Drug: Scheme I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme I: chloroquine phosphate (150 mg) at 25mg/kg/day for three days (10mg/kg on day 1, 7.5mg/kg on days 2 and 3) plus primaquine (15 mg) at 0.25mg/kg/day for fourteen days
Trial: 11562727
Drug: Scheme II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme II: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for seven days
Trial: 11562727
Drug: Scheme III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme III: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for five days
Trial: 8162980
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at 2 l.min‐1 at rest
Trial: 8162980
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities (as reported in questionnaire)
Trial: 8162980
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (prescribed based on blood gas measurements at rest)
Trial: 4939600
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg four times daily for four weeks
Trial: 4939600
Drug: Salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 2 mg four times daily for four weeks
Trial: 27317878
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/efavirenz 300/300/600 mg
Trial: 23783829
Drug: Self‐administered implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered implementation intention
Trial: 16825290
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of VEGF‐A(165) plasmid followed by G‐CSF (10 microg/kg/day for 6 days)
Trial: 16825290
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of VEGF‐A(165) plasmid
Trial: 16825290
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of placebo
Trial: 15210258
Drug: Drug consultations
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug consultations in French and Bambara
Trial: 8269656
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow rate of 250 cc/min
Trial: 8269656
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow rate of 350 cc/min
Trial: 8269656
Drug: Blood flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow rate of 450 cc/min
Trial: 8269656
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between the three different blood flow rates (250, 350, 450 cc/min)
Trial: 30445682
Drug: Synergy 1
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergy 1 (10 g)
Trial: 19019658
Drug: O(2)/N(2)O FGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O(2)/N(2)O FGF setting change from 6 to 0.7 L per minute after three minutes
Trial: 12805060
Drug: therapy‐related AML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy‐related AML (t‐AML)
Trial: 10739409
Drug: 1.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/day of haloperidol
Trial: 10739409
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day of haloperidol
Trial: 10739409
Drug: 5.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/day of haloperidol (for non-responders)
Trial: 8796820
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid bolus with 1 L of normal saline administered over 30 minutes
Trial: 3127916
Drug: Intravenous DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous DDAVP (0.3 micrograms/Kg)
Trial: 3127916
Drug: Subcutaneous DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous DDAVP (0.3 micrograms/Kg)
Trial: 16547088
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg ml(-1) (0.2%)
Trial: 16547088
Drug: Prilocaine 5
RxNorm normalized name: prilocaine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 5 mg ml(-1) (0.5%)
Trial: 10924807
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl (112 microg bolus followed by 0.04 microg/kg per min infusion)
Trial: 10924807
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fentanyl (56 microg bolus followed by 0.02 microg/kg per min infusion)
Trial: 10924807
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (50 cc bolus followed by 45 cc/h infusion)
Trial: 7717552
Drug: Fentanyl (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (both doses)
Trial: 7796344
Drug: 100 IU
RxNorm normalized name: Vitamin E 100 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU of salmon calcitonin intranasally daily for 1 year
Trial: 7796344
Drug: Placebo intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal spray daily for 1 year
Trial: 2121325
Drug: Nitroglycerin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (1.5 micrograms/kg/min) with oral captopril (63 +/- 8 mg/day)
Trial: 619947
Drug: Clonidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (300 μg)
Trial: 619947
Drug: UK-14,304 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-14,304 (750 μg)
Trial: 19628319
Drug: High-dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6, and 2 mg of vitamin B12)
Trial: 16733228
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 mg/day)
Trial: 14998605
Drug: Declined entry
RxNorm normalized name: Sentry HC Worm X DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Declined entry into randomised clinical trials of adjuvant cancer therapy
Trial: 11150899
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg diazepam
Trial: 28712786
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 12 months
Trial: 3630891
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin pretreatment
Trial: 17542110
Drug: Micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplement containing vitamin A, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, calcium pantothenate, vitamin C, vitamin E, iron, lysine, and calcium, daily for 9 months
Trial: 12594004
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 50 mg denaverine hydrochloride
Trial: 12594004
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 50 mg denaverine hydrochloride in aqueous solution
Trial: 12594004
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 50 mg denaverine hydrochloride in aqueous solution
Trial: 12594004
Drug: Suppository formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository formulation of 50 mg denaverine hydrochloride
Trial: 9360031
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (30 min, 3-4 times weekly for 6 weeks)
Trial: 1551298
Drug: Phenylpropanolamine hydrochloride
RxNorm normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine hydrochloride 25 mg p.o. four times a day (total, 10 doses)
Trial: 3838406
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg of SIN-1
Trial: 30861550
Drug: Prophylactic dose
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dose apixaban
Trial: 30202851
Drug: DZX +
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DZX + metformin (DZX + MTF)
Trial: 30202851
Drug: DZX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX treatment
Trial: 24811940
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume ≤6 ml/kg PBW